realitycheck4u wrote: I wrote this so you can understand it better.
TH targets two massive markets and has one drug moving into PH3 after 10 years of safety proven in HIV patients.
TH’s oncology program just received FDA Fast Track status from earlier results and TH will be dosing patients shortly in a phase 1 study, after what can only be described as spectacular results in the lab with mice. This potentially revolutionary program is based around the idea of a Peptide, which is like a suitcase with sticky material on the outside (but this sticky material only works if there is a ‘receptor’ with other sticky material on it - which happens to be Sortilin. Therefore, TH’s Peptide will only stick to the membrane of a cancer sell which are expressing Sortilin - and this is significant as it is now known that Sortilin is within 5 different types of solid growth tumours. They are 1.2.3.4.5. (List them). 50% to 60% of patients who die from Cancer are actually killed by a cancer that is over-expressing Sortilin - so this is very important. Sortilin is like a hidden flag which is being held up, and which only TH’s is targeting (and which is has IP protection on). What happens is that TH’s Peptide (it’s known also as a PDC) hunts for cells expressing Sortilin, (these cancer cells) and then as soon as it gets near to these cancers cells, the sticky material actually binds itself to the cancer cell membrane. Once the PDC is bound to the sortilin receptor, both are internalized into the cancer cell through a process called endocytosis. Once inside the cancer cell, the higher acidity, in comparison with the bloodstream, allows the release of the free anticancer agent. The sortilin receptor is the target to allow selective intake of the drug into the cancer cell. The other key part is the 17 amino acids peptide that has high affinity to the sortilin receptor that will lead to the specific binding of the two parts. The other critical feature of the peptide is the possibility to link to it two drug molecules through the use of a linker stable in the bloodstream, but unstable inside the cancer cells due to higher acidity. So this platform through the use of a proprietary peptide allows the selective intracellular delivery of cancer drugs. The advantages of this technique is that it allows higher concentration of the drug delivered directly to a cancer cell, and do that delivery INSIDE the cancer cells. It’s like Uber, but it does not drop you off 5 blocks away, but it targets the delivery right into your living room. And, therefore, their Sort+ technology can actually deliver LESS of a cancer killing drug(s) with the same affect (as it’s delivered to your living room) or, it can deliver more of a dose to the actual cancer cells -> while at the same time there is a MUCH lower concentration impacting other healthy cells!!!!!!, leading to higher anti-cancer efficacy and this has show a lower toxicity in animal models with human cancer xenograft overexpressing the sortilin receptor. You can put other drugs into TH’s Suitcase. In fact you can put a combination of drugs in the suitcase. For now, TH is testing TWO DIFFERENT drugs on 5 or 6 types of cancers. It’s all very exciting. And, it’s a potentially blockbuster investment. Let’s hope is works. Regardless if you invest or not.